Blood Group B Transferase Market by Manufacturers, Regions, Type and Application, Forecast To 2026 Assay Biotechnology, DLDEVELOP, Aviva Systems…

The latest research report on the Blood Group B Transferase Market Industry Analysis, Market Size, Opportunities and Forecast, 2020 2028 provides a comprehensive assessment of the Blood Group B Transferase market for the forecast period from 2020 to 2028, including market values for the years 2018 and 2019. The investigative report provides a detailed analysis of the impact of COVID-19 on various segments in the Blood Group B Transferase market based on product type, application, and end-use across numerous countries around the world. Further, the report also provides insights into market developments, trends, supply and demand changes across various regions across the globe. Thereby, the report provides a holistic view on the Blood Group B Transferase Market in order to help decision makers with various strategic insights and future outlook. The Blood Group B Transferase market is expected to witness continued growth during the forecast period from 2020 to 2028.

Leading companies reviewed in the Blood Group B Transferase Market report are: Assay Biotechnology, DLDEVELOP, Aviva Systems Biology, Abbexa, EIAab, Cloud-Clone

Get Free Exclusive Sample of this Premium Report at: https://www.zealinsider.com/report/5270/blood-group-b-transferase-market#sample

The report covers various aspects of the Blood Group B Transferase market segmented into product type, application and end-use. The report provides market numbers for the years 2018 and 2019 based on actual market findings also market estimates for forecasts for the period from 2020 to 2020 for each of the products types, applications and end-use segments.

Furthermore, the report includes a detailed competitive analysis among the market participants in the Blood Group B Transferase market. The report offers an in-depth comparative analysis of the competitors in the market based on their product offerings, market share and geographic presence. Some of the leading companies covered in the report include Assay Biotechnology, DLDEVELOP, Aviva Systems Biology, Abbexa, EIAab, Cloud-Clone

***NOTE***

We are continuously monitoring the market developments and changes occurring as a direct or indirect impact of the ongoing COVID-19 pandemic. Thereby, we are in a position to provide information on the market values and trends for both pre-COVID-19 and post-COVID-19 scenarios.

Target audiences for the report include:

Blood Group B Transferase Market Segmentation, By Product Type:Antibodies, Elisa Kits, Protein, Peptide, Others

Blood Group B Transferase Market Segmentation, By Application:Human, Mouse, Monkey, Others

Blood Group B Transferase Market Segmentation, By Geography:

Access Full Report information, here: https://www.zealinsider.com/report/5270/blood-group-b-transferase-market

Key Focus Areas in the Report:

See the original post here:
Blood Group B Transferase Market by Manufacturers, Regions, Type and Application, Forecast To 2026 Assay Biotechnology, DLDEVELOP, Aviva Systems...

Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional…

Tel Aviv, Israel , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Adding to a growing roster of partners, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced that it has entered into and commenced a collaborative development program with Sweden-based XNK Therapeutics, a pioneer in natural killer (NK) cell-based therapies.

This latest agreement demonstrates the continued progress and operational momentum we are continuing to generate, further validating our strategic vision and potential revenue opportunities, commented Dr. Shai Yarkoni, Chief Executive Officer. We join an already prestigious group of organizations that are currently collaborating with XNK Therapeutics, including the Karolinska Institute and the Royal Institute of Technology, and we are looking forward to fostering a long-term business and commercial collaboration. We remain focused on commercializing our functional cell selection technology so patients and markets can benefit from the proven safety profile and better outcomes of a broad range of cell and gene therapies.

Under the terms of the agreement, Cellect will help improve XNK Therapeutics technology platform, for targeting cancer across a wide range of indications. Cellect expects to expand the business arrangement based on the outcomes of the ongoing studies at XNK Therapeutics. Cellects functional cell selection technology has the potential to significantly improve the consistency and manufacturing efficiency in autologous as well as future allogeneic transplantation

XNK Therapeutics is expected to leverage Cellects simple, safe and inexpensive process as part of its efforts to create the next generation version of its innovative therapy platform. I am excited that we continue developing the next generation of XNK Therapeutics technology platform and looking forward to the collaboration with Cellect says Johan Liwing CEO of XNK Therapeutics.

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

Story continues

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Companys ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

ContactCellect Biotechnology Ltd.Eyal Leibovitz, Chief Financial Officerwww.cellect.co+972-9-974-1444

Or

EVC Group LLC Michael Polyviou(732) 933-2754mpolyviou@evcgroup.com

More here:
Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional...

Bio-convergence may be next big thing from Israel – Cleveland Jewish News

Testing new cancer drugs on 3D-printed tumor cells. Analyzing the gut microbiome to determine the best medicine for Crohns disease. Identifying genetic pairs so that a drug can turn off a cancer cell.

These are just a few of the overlaps of biology, physics, computer science, mathematics, engineering, materials science and nanotechnology that make up the new field of bio-convergence.

Testing new cancer drugs on 3D-printed tumor cells. Analyzing the gut microbiome to determine the best medicine for Crohns disease. Identifying genetic pairs so that a drug can turn off a cancer cell.

These are just a few of the overlaps of biology, physics, computer science, mathematics, engineering, materials science and nanotechnology that make up the new field of bio-convergence.

The Israel Innovation Authority is betting on bio-convergence as the next big thing from the startup nation.

The IIA announced in January that it would invest up to about $30 million in bio-convergence technologies and companies. In July, the governmental agency added a call for R&D proposals from academia and industry in the field of bio-convergence with a budget of $4 million.

In August, a third call for bio-convergence proposals this time for collaboration between Israeli and South Korean companies came with a $4.16 million budget and a plan to provide grants up to 50 percent of R&D expenses.

The bio-convergence push is a bit of a departure for the IIA.

We usually work in a bottom up approach and very seldom intervene and select a specific technological field for strategic investments, Anya Eldan, vice president of the IIAs Startup Division, said. In the past it has been cyber and fintech. Now weve identified bio-convergence as the next growth engine for the Israeli economy.

Developing disease-fighting drugs the old-fashioned way takes decades and billions of dollars. The new era of pharma will see researchers from multiple disciplines working together.

When we started to look for the next growth engine, we realized that none of the major pharmaceutical companies are invested in bio-convergence, Eldan explained. Theyre looking at biology but theyre not sure how to approach it.

Israel, however, is a small country where everyone knows one another, making it relatively easy to put together multidisciplinary teams.

On a folksier level, Eldan said Israelis large Friday night Shabbat dinners naturally foster collaboration.

People have to find things to talk about. So, a doctor mentions at the dinner table he has a patient without a solution and the engineer in the family says, That shouldnt be, and from there a startup is born.

This trend could have a major impact on the global health care system crisis. Health expenditures worldwide were expected to reach $10 trillion by 2022 even before the advent of COVID-19. Half the U.S. population is considered chronically ill, accounting for some 85% of the total expenditure on healthcare services.

The IIA has identified approximately 80 companies working in the field of bio-convergence. Much of the knowhow is tucked away in Israels academic centers.

Ronit Satchi Fainaro is a prime example.

Named Woman of the Year by the Israeli business publication Globes in 2019, Satchi Fainaro heads the 30-person cancer research and nano-medicine laboratory in the department of physiology and pharmacology at Tel Aviv University.

Satchi Fainaros lab includes research associates in biology, chemistry, medical engineering, bioinformatics and even an architecture student, she said. We are living in the post-genomic era, so theres a lot of room for computer science.

Satchi Fainaros lab developed a method for 3D printing cancerous brain tumors using MRI on images.

We do the image analysis and convert it to a file that a 3D printer can read. Then we create a 3D-printed tumor its like a Mini-Me of that tumor, she said, referring to the Mike Meyers character from the Austin Powers films.

Satchi Fainaros lab creates not one but up to 20 mini-tumors, which are then connected to a set of tubes and pumps that deliver simulated blood and most importantly chemotherapy or other cancer treatments. That allows physicians to test drugs on a perfect copy of the actual tumor.

Satchi Fainaro is also working on an immunotherapy nano-vaccine for melanoma and an immune-modulated response against Covid-19.

Jonathan Solomon and Assaf Oron are the CEO and chief business development officer, respectively, of BiomX, another Israeli bio-convergence pioneer.

BiomX is working on a treatment for Crohns and other inflammatory bowel diseases by sequencing the bacteria in a patients microbiome in order to deliver a gut-punch to the exact bacteria causing symptoms.

BiomXs technology is based on the hypothesis that these diseases are driven by the microbiome and that specific bacteria seem to be pro-inflammatory and antibiotic resistant, Solomon tells ISRAEL21.

Bacteriophage image courtesy of BiomX

Bio-convergence techniques assure that a patient receives the right phages a type of virus that infects bacteria to kill only the offending microbes.

Antibiotics are very indiscriminate killers, Solomon said, which leads to the killing of both harmful and beneficial bacteria and, in many cases, the development of antibiotic-resistant bacteria. Phages are very precise. There are no side effects.

Beyond IBD, acne and liver disease are next on BiomXs list. Even cancer is a possibility.

BiomXs technology was initially developed and licensed from the Weizmann Institute in Rehovot. The company has 100 employees and is publicly traded in the United States.

Then theres Pangea, whose bio-convergence niche is synthetic lethality.

Its a very simple notion with a confusing name, chief technology officer Tuvik Beker said.

The basic idea is that genes often act in pairs. If a gene is acting unnaturally in a tumor (for example, it may be shut down due to mutation or abnormal expression), identifying and shutting down the genes partner can selectively kill the malignant cells.

Pangea brings the computational element.

If there are 20,000 genes in the human genome, simple math means there are about 400 million gene pairs, Beker explained. To test all these pairs for synthetic lethality is very challenging.

As a result, most companies restrict themselves to a couple of hundred genes that they know are important in cancer. Pangea, by contrast, looks for paired genes that are vulnerable to collateral damage, not just the ones driving the tumor, Beker said.

The Tel Aviv-based company hopes to launch its service commercially as early as 2021 with a focus on providing personalized treatment recommendations.

See the original post here:
Bio-convergence may be next big thing from Israel - Cleveland Jewish News

New Nanomedicine Approach Could Improve Effectiveness of COVID-19 Vaccine – AZoNano

Written by AZoNanoOct 29 2020

Researchers led by the University at Buffalo (UB) have devised a new method that could enhance the effectiveness of vaccines against the novel coronavirus, the virus that is responsible for causing COVID-19.

Jonathan F. Lovell, PhD, an associate professor in the Department of Biomedical Engineering at UB, is the principal investigator of the study titled SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination, published online in the Advanced Materials journal on October 28th, 2020.

COVID-19 has resulted in an uncontrollable global pandemic, which has infected a minimum of 40 million people around the world and resulted in over 220,000 deaths in the United States alone. As the disease started spreading in early 2020, biomedical researchers have been working actively to develop an effective vaccine.

Lovell thinks that one solution could be to develop vaccines that partly imitate the virus structure. One of the proteins on the virussituated on the characteristic COVID spikeincludes a component known as the receptor-binding domain, or RBD, which is its Achilles heel. Lovell stated that antibodies against this part of the virus have the ability to neutralize the virus.

It would be appealing if a vaccine could induce high-levels of antibodies against the RBD. One way to achieve this goal is to use the RBD protein itself as an antigen, that is, the component of the vaccine that the immune response will be directed against.

Jonathan F. Lovell, Associate Professor, Department of Biomedical Engineering, University at Buffalo

The researchers speculated that if the RBD is transformed into a nanoparticle (similar in size to the virus itself) rather than retaining it in its natural form as a tiny protein, it would produce higher levels of neutralizing antibodies and its potential to produce an immune response would increase.

Earlier, Lovells group had designed a technology that enables the simple transformation of small, purified proteins into particles by using liposomes, or small nanoparticles developed from naturally occurring fatty components.

In the latest study, the team added a unique lipid known as cobalt-porphyrin-phospholipid or CoPoP inside the liposomes. The lipid allows the RBD protein to quickly bind to the liposomes, developing more nanoparticles that produce an immune response, stated Lovell.

The researchers noticed that when the RBD was transformed into nanoparticles, it retained its correct, three-dimensional shape and the particles were stable in incubation conditions, analogous to those present in the human body.

High antibody levels were induced in laboratory rabbits and mice immunized with the RBD particles. When compared to other materials integrated with the RBD to improve the immune response, only the method with particles containing CoPoP ensured a powerful response.

According to Lovell, other vaccine adjuvant technologies cannot transform the RBD into particle-form.

We think these results provide evidence to the vaccine-development community that the RBD antigen benefits a lot from being in particle format. This could help inform future vaccine design that targets this specific antigen.

Jonathan F. Lovell, Associate Professor, Department of Biomedical Engineering, University at Buffalo

This research was funded by the U.S. National Institutes of Health, and the Facility for Electron Microscopy Research (FEMR) at McGill University. FEMR is supported by the Canadian Foundation for Innovation, Quebec Government, and McGill University.

Huang, W.-C., et al. (2020) SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination. Advanced Materials. doi.org/10.1002/adma.202005637.

Source: http://www.buffalo.edu/

See the rest here:
New Nanomedicine Approach Could Improve Effectiveness of COVID-19 Vaccine - AZoNano

Market Players Eye Opportunities in Emerging Economies to Gain Ground in the Healthcare Nanotechnology (Nanomedicine) Market 2015 2021 – Eurowire

The Healthcare Nanotechnology (Nanomedicine) Market research report added by Market Study Report, LLC, provides a succinct analysis on the recent market trends. In addition, the report offers a thorough abstract on the statistics, market estimates and revenue forecasts, which further highlights its position in the industry, in tandem with the growth strategies adopted by leading industry players.

The Healthcare Nanotechnology (Nanomedicine) market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Healthcare Nanotechnology (Nanomedicine) market and the trends that will prevail in this industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

What pointers are covered in the Healthcare Nanotechnology (Nanomedicine) market research study?

The Healthcare Nanotechnology (Nanomedicine) market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Healthcare Nanotechnology (Nanomedicine) market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Healthcare Nanotechnology (Nanomedicine) market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Healthcare Nanotechnology (Nanomedicine) market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Healthcare Nanotechnology (Nanomedicine) market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Healthcare Nanotechnology (Nanomedicine) market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

Some of the Major Highlights of TOC covers:

See the article here:
Market Players Eye Opportunities in Emerging Economies to Gain Ground in the Healthcare Nanotechnology (Nanomedicine) Market 2015 2021 - Eurowire

Global Nanobots Market 2020 | Research Report Covers | (COVID-19 Analysis) | Industry Research, Drivers, Top Trends | Global Analysis And Forecast to…

Global Nanobots Market Report Provides Detailed Study Of Industry Players, Business Strategies, Latest Developmental Trends, And Market Growth Rate

The globalNanobots marketreport offers a thorough study of the market in the estimated period. The important players Xidex Corp, Zymergen Inc, Synthace Limited, Ginkgo Bioworks, Advanced Diamond Technologies, Advanced Nano Products Co Limitedin the global Nanobots market are mentioned along with their strong points as well as weak points in this report. It covers almost all aspects of the global Nanobots market including challenges, demand, drivers, and opportunities. The report reviews the impact of these aspects on every market region as well. The value chain analysis and vendor list are also included in the global Nanobots market report.

Ask For Free Sample PDF of Nanobots Market Report

{We Provide Free Sample copy as per your Research Requirement, also including COVID 19 impact analysis}

The global Nanobots market research report emphasizes the presentation of the in-depth market segments {Microbivore Nanorobots, Respirocyte Nanorobots, Clottocyte Nanorobots, Cellular Repair Nanorobots}; {Nano Medicine, Biomedical, Mechanical, Other applications}. The Nanobots market is assessed on the basis of revenue (USD Million) as well. The performance of the important players, vendors, and suppliers influencing the market is also incorporated in the global Nanobots market research report. The majority of the information, together with projected statistics, is presented in the report with the help of tables and graphics. This presentation technique helps the user to understand the market scenario in an easy way.

Various practical tools are used for assessing the development of the global Nanobots market in the future period. The global Nanobots market report offers an outline of the market on a global level. It helps users to decide their next business move and propel their businesses. The index growth and competitive framework of the global Nanobots market over the projected period is involved while reviewing the Nanobots market. The global Nanobots market is also bifurcated regionally North America (the U.S., Canada, and Mexico), South America (Brazil, Argentina, Chile, Colombia), Europe (Spain, Russia, Germany, Italy, France, and UK), Asia-Pacific (Japan, Korea, India, China, Australia, and South-east Asia), The Middle East and Africa (Egypt, South Africa, GCC Countries) as well.

Enquire about COVID-19 Updates for This Report:https://www.marketdataanalytics.biz/global-nanobots-market-report-2020-by-player-region-type-49438.html#inquiry-for-buying

Major Questions Answered in Report:1. Which are the growth factors likely to help the market reach to the next level?2. What is the expected growth rate during the forecast period?3. What are the latest opportunities and challenges for Nanobots market in the future?4. Which are the key market players?

The global Nanobots market is studied in terms of technology, topography, and consumers. The report also covers the market volume during the estimated period. The distinctiveness of the global Nanobots market research report is the representation of the Nanobots market at both the global and regional level.

Key Reasons for Purchasing Global Nanobots Market Report:

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities Key competitive players and regional distribution will help find prospective market analytics Report will strengthen the investors decision-making processes

To get more information on this Premium Report::https://www.marketdataanalytics.biz/global-nanobots-market-report-2020-by-player-region-type-49438.html

The rest is here:
Global Nanobots Market 2020 | Research Report Covers | (COVID-19 Analysis) | Industry Research, Drivers, Top Trends | Global Analysis And Forecast to...

Covid-19 impact on Antibacterial Nanorobots Leading Players during the Forecast Period 2020-2026| Bruker, JEOL, Thermo Fisher, Ginkgo Bioworks, Oxford…

Global Freezing Drying Equipments Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)

Global Antibacterial Nanorobots Market Report offers an entire study of the Impact of COVID-19 on Antibacterial Nanorobots Market, Industry Outlook, Opportunities in Market, and Expansion By 2026 and also taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of this also as a future scenario of the worldwide Antibacterial Nanorobots industry. Research techniques like PESTLE and SWOT analysis are deployed by the researchers. They need also provided accurate data on Antibacterial Nanorobots production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding of the general existing and future market situation.

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Antibacterial Nanorobots Market:

Antibacterial Nanorobots Market competition by top manufacturers/Key player Profiled:Bruker, JEOL, Thermo Fisher, Ginkgo Bioworks, Oxford Instruments, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Park Systems

The study objectives of Antibacterial Nanorobots Market report are: 1.To identify opportunities and challenges for Global Antibacterial Nanorobots.2.To provide insights about factors affecting market growth. To analyze the Antibacterial Nanorobots market based on various factors- price analysis, supply chain analysis, SWOT analysis, etc.3.To identify and analyze the profile of leading players involved within the manufacturing of worldwide Antibacterial Nanorobots.4.To provide country-level analysis of the market regarding the present Antibacterial Nanorobots market size and future prospective.5.To examine competitive developments like expansions, new product launches, mergers & acquisitions, etc., in Global Antibacterial Nanorobots.6.To provide a detailed analysis of the market structure alongside forecast of the varied segments and sub-segments of the worldwide Antibacterial Nanorobots market.

At the beginning of 2020, COVID-19 disease began to spread around the world, millions of people worldwide were infected with COVID-19 disease, and major countries around the world have implemented foot prohibitions and work stoppage orders. Except for the medical supplies and life support products industries, most industries have been greatly impacted, and Antibacterial Nanorobots industries have also been greatly affected.

In the past few years, the Antibacterial Nanorobots market experienced a growth of xx, the global market size of Antibacterial Nanorobots reached xx million $ in 2020, of what is about xx million $ in 2015.

From 2015 to 2019, the growth rate of global Antibacterial Nanorobots market size was in the range of xxx%. At the end of 2019, COVID-19 began to erupt in China, Due to the huge decrease of global economy; we forecast the growth rate of global economy will show a decrease of about 4%, due to this reason, Antibacterial Nanorobots market size in 2020 will be xx with a growth rate of xxx%. This is xxx percentage points lower than in previous years.

As of the date of the report, there have been more than 20 million confirmed cases of CVOID-19 worldwide, and the epidemic has not been effectively controlled. Therefore, we predict that the global epidemic will be basically controlled by the end of 2020 and the global Antibacterial Nanorobots market size will reach xx million $ in 2025, with a CAGR of xxx% between 2020-2025.

Segmentation by Product:

50-100 nm> 100nm

Segmentation by Application:

NanomedicineBiomedical Science

Click Here For Best Discount: https://www.reporthive.com/request_customization/2525647

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

Global Antibacterial Nanorobots Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Antibacterial Nanorobots Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons To Buy: Make strategic business decisions using in-depth historic and forecast market data associated with the Antibacterial Nanorobots market, and every category within it.Extensive price charts draw particular pricing trends within recent yearsPosition yourself to realize the most advantage of the Antibacterial Nanorobots markets growth potentialTo understand the latest trends of the Antibacterial Nanorobots marketTo understand the impactful developments of key players within the market, their strategic initiatives and comprehensively study their core competencies

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2525647

Table of Contents

Report Overview:It includes major players of the global Antibacterial Nanorobots Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Antibacterial Nanorobots Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Antibacterial Nanorobots Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Antibacterial Nanorobots Market by application, it gives a study on the consumption in the global Antibacterial Nanorobots Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Antibacterial Nanorobots Market are profiled in this section. The analysts have provided information about their recent developments in the global Antibacterial Nanorobots Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Antibacterial Nanorobots Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Antibacterial Nanorobots Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Antibacterial Nanorobots Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Read the original post:
Covid-19 impact on Antibacterial Nanorobots Leading Players during the Forecast Period 2020-2026| Bruker, JEOL, Thermo Fisher, Ginkgo Bioworks, Oxford...

Quilts for pancreatic cancer patients and research – Royal Society of Chemistry

Dr Clare Hoskins, a Reader in Strathclydes Department of Pure and Applied Chemistry, is leading Quilts4Cancer, along with Dr Kirsty Ross, the Departments Outreach Officer. The programme is being launched to coincide with Pancreatic Cancer Awareness Month in November.

Dr Hoskins said: "Funds for cancer research have dropped significantly in the pandemic but we aim to raise awareness of chemistry research across the UK towards better therapies for pancreatic cancer, as well as raising awareness of its signs and symptoms.

"We chose to have quilts made because its known that chemotherapy patients get cold during their treatment. The therapy has serious side effects but we want to raise awareness of the new technology and compounds coming through; a lot of work is being done on making treatment safer, with fewer side effects.

"Were asking for researchers in the chemical sciences to send simple diagrams based on their research, with small summaries of what it is and who is carrying it out. It could show the chemical structures of treatments or technology such as ultrasound equipment.

Picture: University of Strathclyde

Here is the original post:
Quilts for pancreatic cancer patients and research - Royal Society of Chemistry

Nanorobotics Market Research, Growth Opportunities, Analysis and Forecasts Report 2020-2026 – The Think Curiouser

AllTheResearchs published a research report on the Nanorobotics market, which represents a study for the period from 2020 to 2026. The research provides a near look at the market scenario and dynamics impacting its growth. This report highlights the crucial developments along with other events happening in the market which are marking on the growth and opening doors for future growth in the coming years. Additionally, the report is built based on the macro- and micro-economic factors and historical data that can influence the growth.

The global Nanorobotics market was valued at US$ 5.11 Bn in 2018 and is expected to reach US$ 10.71 Bn in 2026, growing at a CAGR of 9.9% during the forecast period.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.alltheresearch.com/sample-request/299

Key Players:

The global Nanorobotics market has been comprehensively analyzed and the different companies that occupy a large percentage of the market share in the regions mentioned have been listed out in the report. Industry trends that are popular and are causing a resurgence in the market growth are identified. A strategic profile of the companies is also carried out to identify the various subsidiaries that they own in the different regions and who are responsible for daily operations in these regions.

The Key Players Covered in Nanorobotics Market Study are:

How Report will help you to make decisions for business:

Before purchasing the report, lets discuss with the analyst @ https://www.alltheresearch.com/speak-to-analyst/299

Nanorobotics Market Segmentation

Nanorobotics market is split by Type and by Application. For the period 2015-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market Segmentation by Type:

Market Segmentation by Applications:

COVID-19 Impact on Nanorobotics Market:

The outbreak of COVID-19 has brought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Nanorobotics Market. Overall competitive landscape and market dynamics of Nanorobotics has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Nanorobotics Market.

Get Brief Information on Pre COVID-19 Analysis and Post COVID-19 Opportunities in Nanorobotics Market @ https://www.alltheresearch.com/impactC19-request/299

Research objectives:

Browse Full Research report along with TOC, Tables & Figures: https://www.alltheresearch.com/report/299/Nanorobotics

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference.While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan S.

Email: [emailprotected]

Phone: +1 (407) 768-2028

Read the original here:
Nanorobotics Market Research, Growth Opportunities, Analysis and Forecasts Report 2020-2026 - The Think Curiouser

UTRGV to offer 10th school of podiatric medicine in entire nation – KGBT-TV

EDINBURG, Texas (KVEO) UTRGVSSchool of Medicineis growing againbyaddingapodiatry program the only one inTexas.

Historically, anyone inTexaswho wanted to be a podiatrist had to leave the state to get a degree to come back,Dr. Lawrence Harkless,UTRGV School of Podiatry interim dean said.

Dr.Harkless came out of retirementto serve as the new schools deanand prepare the academic plan.

We will be taking the classes the medical school takes in the first two years,and then we will start teaching more podiatry-specific courses earlier,he said.

Dr. Harkless previously helped establish aCollege ofPodiatricMedicine inPomona,California, and saysstudent mentorship will be at the forefront of this new program.

The foundation for that would be learn, serve, lead,he said.

According to theAmericanDiabetesAssociation, theRGV has a diabetes rate three times higher than the national average, whichDr.Harkless says makes the area an ideal spot fortheschool.

(People) Can really stay inthecommunity where they grewup andserve,he said.

The inaugural class will be welcomed in the fall of 2022,andUTRGVisalready looking to hire 20 faculty with a passion for both teaching as well as research.

Tohaveexcellence in a student, every faculty member has to be excellentbecause they have to be able to teach thatwhetherin basic science, two years theory andfactorwhetherin clinical years, he said.

Along with theSouthTexasDiabetes andObesityInstitute ofBrownsville,Dr.Harkless says theRGV could become medical leaders over genetics and genomics of the feet.

Read the original here:

UTRGV to offer 10th school of podiatric medicine in entire nation - KGBT-TV

Burnout: The Experience of Women In Medicine During COVID-19 – The Doctor Weighs In

Women in medicine are at risk of physician burnout due to COVID-19 due to many different factors, including:

Further, they must continue to deal with all of the job-related stress that existed before the pandemic, including:

No wonder women in medicine are feeling overwhelmed and are at risk of burnout.

Since the onset of COVID-19, people worldwide have had to learn to adapt to change quickly. The problem with this, however, is that our brain doesnt like change. It likes to predict the future and when we face change, this means one thing: uncertainty.

The pandemic has turned the world as we knew it upside-down. Things we previously took for granted, like getting together with friends or going to work, became risky.

In addition to dealing with the possibility of contracting COVID through everyday activities, medical professionals are also at increased risk of contracting the virus through the treatment of their sick patients.

Related Content:Survey Shows Women in Medicine Still Face InequitiesPrioritizing Healthcare Workers Mental Health During COVID-19

While they are needed now more than ever, medical professionals are losing their jobs and experiencing a reduction in pay and hours. Those who have not yet been affected are worried about the future of their career and financial stability.

Because most schools in the United States have switched over to a digital format, much of childcare and homeschooling have fallen on parents. Traditionally, women have been the primary ones to handle work within the home. [3] Therefore, it is not a far stretch to imagine that they are also the ones who are taking on most of these domestic tasks now.

While these women might be high achievers, many say they are working hard for their families. The trouble is their career takes up so much of their time that they have less time to spend with their loved ones. Even when they have the time, they often experience emotional exhaustion, [4] which may keep them from being fully present.

Perhaps, that is why 40 percent of female physicians end up leaving or cutting back their hours by their sixth year [5]. A similar trend can be seen with female nurses whose turnover rates are purported to be as high as 38 percent.[6] However, working less can bring up additional stress related to paying back student loans and other financial debt.

For all these reasons, being a woman in medicine now more than ever can feel like being in survival mode. Indeed, when demands are excessive and resources are short, this is a recipe for burnout [7].

As it turns out, 42 percent of physicians reported being burned out according to a recent online survey [8]. A similar trend can be seen with nurses who normally experience emotional pressures in their jobs which, during a pandemic, can lead to stress and burnout. [9]

When these professionals are not at their best, they suffer a decrease in energy, morale, and job performance. And, the quality of their medical care goes down.

The effect of this trickles down to patients who receive poorer quality care. And they may suffer higher rates of infections and increased mortality rates due to medical errors. [10]

Some women in medicine may turn to junk food or overindulge in drugs or alcohol to cope with stress. Such maladaptive coping translates into weight gain, poorer health, and addictions. All of these things have further consequences that negatively affect sleep, mood, and relationships.

While the external stressors they face are real, it is up to the individual to learn to manage their thinking to avoid feeling anxious, overwhelmed or burned out. This is possible even during COVID-19.

In addition to environmental stressors, part of the reason why anxiety and burnout are an epidemic among healthcare workers is because of the stigma around mental health in the field of medicine.

There is an expectation that healthcare providers are superhuman. And, that they can manage to deal with emotionally draining and sometimes traumatic experiences while navigating challenging work-related conditions without being affected. This is clearly unrealistic and very damaging to their long-term well-being.

Nevertheless, not all hope is lost. The key to staying afloat amid the chaos is self-management. It may seem that the reasons for the stress are external factors and therefore beyond your control. However, our response to stress is a product of our minds.

Think of a time when you were in the same situation as someone else. While you may have been negatively affected by the circumstances at the time, your friend or colleague was unphased.

The reason for this difference in outcomes relates to perception. It is not what happens to us that makes us feel how we do. Rather, it is how we think about what happens to us that leads to those feelings.

When we misunderstand someones intention, we can feel upset by our interpretation. Once we realize what they truly meant, our perception shifts. Consequently, so do our feelings.

The same is true in the workplace. It is your thinking that creates your current emotional state, not the circumstances. When you shift your mindset, you shift your anxiety into a state of calm.

The next time you find yourself ruminating about mistakes youve made or worrying about the future, bring yourself back to the present moment. Recognize that you have a choice about where you focus your mind.

The world around you will remain imperfect. The healthcare system in which you work will continue to be deeply flawed.

When you fixate on what should be different, youll only feel frustrated. Instead, focus inward on what you can control. This is because the only thing you have control over is yourself.

By learning to manage your thinking, you can make positive changes, such as:

The responsibility of self-management and self-care may seem like an added burden to your already burdened life. However, by increasing Emotional Intelligence and managing your energy, you lighten your load.

What may have seemed overwhelming previously may feel easier when your perspective shifts, when you are in a state of balance, and when you are able to accept aspects that exist outside your control.

You are stronger than you realize and no matter what, rememberyou always have a choice.

During the COVID-19 pandemic, women in medicine have been faced with heightened demands and lower than normal resources. This combination can overwhelm and bring about anxiety and burnout.

By focusing internally rather than externally, you can regain control over your reactions and refocus on what really matters long-term.

Follow this link:

Burnout: The Experience of Women In Medicine During COVID-19 - The Doctor Weighs In

Meet the power couple who are changing the face of veterinary medicine – Jill Lopez

Dr. Valerie Marcano and Dr. Seth Andrews are more than just a couple in love, together they are working to make veterinary medicine more diverse - something that the veterinary profession desperately needs help with. In 2013, the profession of veterinary medicine was named the whitest profession by The Atlantic magazine. This report mirrored another report in the Journal of Blacks in Higher Education, which gave veterinary medicine the designation as most segregated of all the health professions.

Dr. Valerie completed her DVM and PhD at the University of Georgia ((2017 and 2020) and is a Poultry Technical Consultant at Elanco Animal Health as well as the chair of the Diversity and Inclusion Committee of the American Association of Avian Pathologists.

Dr. Seth Andrews, the other half of the team, is a Process Engineer with Precision BioSciences. He completed a post-doc at the University of Georgia after earning his PhD in Biological Engineering from the University of Georgia in 2019. He received his Bachelor of Science and Master of Engineering from Cornell University.

As fate would have it, he would meet Valerie at Cornell University. They were both a member of Cornells Alpha Zeta fraternity. Valerie made fun of Seth for eating his pizza with a knife and a fork, but it ended up working out as a beautiful relationship.

Together they created Pawsibilities Vet Med - a web and mobile platform designed to aid in the recruitment and retention of diverse students in the veterinary profession through resources, discussion forums and the showcasing of diverse veterinarians. Pawsibilities aims to connect individuals from underrepresented backgrounds interested in the veterinary profession to both opportunities available and to potential mentors and advisors within the field through a mentorship platform.

Pawsibilities Vet Med pools available resources and provides information about veterinary medicine to educate students about the myriad of paths they may take within the profession. It also provides a forum to discuss the various challenges and pitfalls on the path to becoming a veterinarian or veterinary technician. Pawsibilities Vet Med also showcases veterinarians and veterinary technicians from a variety of backgrounds, to emphasize that anyone from anywhere can join the profession.

Together, they hope to give people of color an easier path into veterinary medicine, while also enriching the lives of those who have already made it and providing them the care they need. Their work is the perfect example of how veterinarians should be and also what the future can look like if more people think and act like them.

We caught up Dr. Valerie to learn more:

How we met

We met while attendingCornell Universitys Alpha Zeta fraternity during the Fall of 2009. We were both Sophomores.Its a funny story but essentially I made fun of Seth for eating pizza with a fork and knife.

Who DTR (defined the relationship)

I did!

Secrets to working with your spouse

Our secret to working with each other is having lots of patience and utilizing each others strengths. Seth is really good with website design and technical issues, while I am very good at coming up with ideas.

Best part of working together: Being able to communicate when you have ideas and often being on the same page

Worst part of working together:

Talking about work all the time - sometimes we feel like we need to keep working and if we are doing something fun, we feel like we should be working instead. We often have to remind each other that it is ok to take a night off.

Who I admire most and why:

I have a number ofveterinary women that have truly been my rock and inspiration - trailblazers in the profession that have paved the path I walk on. I remember my first visit to the University of Georgia and meeting Dr. Paige Carmichael, at the time the Associate Dean for Academic Affairs, and Dr. Kaori Sakamoto, at the time the Program Coordinator for the UGA College of Veterinary Medicine's Veterinary Medical Scientist Training dual DVM-PhD degree program. I remember being in awe of these highly trained dual board certified DVM and PhD women of color and have been truly fortunate to have had them become mentors and friends.

Best advice I ever received:

Keep your options open. I was set on a specific job after graduation and one of my mentors, and the person who would have been my supervisor in that position told me to keep my options open. I did and have not regretted it one bit.

Why it is time for Pawsibilities Vet Med:

Because diversity promotes growth - within individuals and the profession as a whole. Diversity, paired with proper training in equity and inclusion, brings about wellness in our profession. Mentorship constitutes support - a clan, a village. It supports the concept that we stand on the shoulder of giants and gives us the chance to pave an even better path for those before us.

Looking to advance or start your career in veterinary medicine? Want to give back to the future of veterinary medicine? Both? Sign up here!

Pawsibility Vet Med

Go here to see the original:

Meet the power couple who are changing the face of veterinary medicine - Jill Lopez

Biracial Stanford physician: We must look beyond race in medicine – Scope

In an August column in STAT News, Megan Mahoney, MD, Stanford Health Care's chief of staff, wrote, "In medical school, I was diligently trained to report to my attending physicians the age, race, and gender of my patients -- in that order."

She wondered how a doctor would describe her, a biracial woman, and what the medical consequences might be for her.

For a 1:2:1 podcast, I spoke with Mahoney, a family medicine clinician, about her background; about race and how it plays out in clinical settings; and about what needs to change to overcome systemic racial inequities in the nation's health care system.

This Q&A is edited and condensed from that conversation.

You wrote in your column: "It's time to stop using skin color and race in medicine and see patients for who they really are." It came out of your experience as a biracial woman. Tell me about your parents.

My father was born to Irish-American parents. After graduating from prep school and the U.S. Naval Academy, he married, but he lost his wife to meningitis. He decided to go into the priesthood. As a priest, he began working in Memphis and became very active in the civil rights movement.

My mother was born in Memphis -- the Jim Crow South -- as one of 13 children. Sometimes all the family had to eat were peaches from the trees in their backyard.

She received a full scholarship to a small Catholic college in Kansas. She returned to Memphis after college to teach at a high school. She also was treasurer at the Catholic parish church where my father served, which is how they met.

My mother received a PhD in mathematics, and later was one of the first African-American women in the United States to become a university president. She served as president of Lincoln University of Missouri for seven years.

My father was by her side throughout her career. It was quite a love story.

When were you first aware of being biracial?

I grew up in Columbus, Ohio. I was in kindergarten, the very first day of school, on the playground with a group of kids. They looked at me quizzically, trying to size me up, and asked, "So, what are you?" I had no idea what they were referring to.

Later, at the dinner table, I asked my parents, "There's this question I'm not really sure how to answer." They told me to go back the next day. If I was asked again, I should respond, "I'm mixed." I felt very prepared. I went back and was asked again, "What are you?" I responded, "I'm mixed up."

As you moved through life, college and medical school, how did being a biracial woman impact you?

For most of my adult life, I was categorized as "other." On applications for various schools, I've had to be limited in how I describe my racial background. They'd ask, White, African American, Asian, Pacific Islander, Hispanic, but there often was not a box that gave me an opportunity to write in, "White and Black."

When I was in high school, my counselors were pushing me towards Ivy League colleges, but I selected a school -- UC Berkeley -- because of its racial diversity.

For the first time, I could experience being surrounded by people of all different backgrounds. I can just share with you that that sense of belonging was truly cherished. For once, I didn't have to be asked, "Where are you really from?" It didn't matter.

In your opinion piece for STAT news, you write that it's time for medicine to look beyond race as a determinant factor and see people as individuals.

The practice of medicine has not truly accounted for mixed-race individuals and lacks the precision to recognize our whole, inclusive identities. A lot of it is based in our history in medicine.

Fortunately, there is now a greater appreciation that race is a social concept, rather than a genetically bounded category, thanks to the genomic revolution. We know now that we, as a species, share 99.9% of our DNA with each other, and that our traits that are typically associated with race are not linked genetically to health-related genes.

There is a greater appreciation for the role of environmental, social and behavioral factors, their influence on health outcomes, and how they probably determine over 70% of what determines health, according to the Centers for Disease Control and Prevention. That exceeds the contribution made by genetics and even medical treatment.

Black Americans have higher rates of morbidity and mortality for COVID-19. Systemic inequities also bear out for Latinos and Indigenous Americans. Are racial inequities baked into the health care system?

Sadly, racism and bias are baked into most, if not all, of our institutions. We need to identify where they exist and then address and change them. I'm committed to that.

A recent Kaiser Family Foundation survey found that one in five Black Americans say they've experienced discrimination while seeking health care in a clinic.

That's a stark statistic, and it likely does reflect the experiences of Black Americans. I think that we as physicians are morally obligated to practice cultural humility -- the fact that we all carry unconscious biases. We all do. We have to become aware of that and approach it with a certain level of humble inquiry, questioning ourselves in how we're practicing medicine.

How do the murders of George Floyd, Breonna Taylor and many others, and the data you're talking about, meet this particular moment? Are we at an inflection point?

I think so. There is a greater interest in raising our collective awareness around these issues. I've also noticed that there is a concerted effort behind wanting to make curricular changes in medical school, so we are understanding how race and racism impacts health and health outcomes.

I'm seeing changes I've never witnessed before, happening throughout our institutions.It's really an important time.

Top image of Megan Mahoney, MD, with a patient by Steve Fisch. Family photos courtesy of Mahoney.

Read this article:

Biracial Stanford physician: We must look beyond race in medicine - Scope

Burrell College of Medicine and NMDOH to host free Halloween flu shot clinic – The Round Up

The New Mexico Department of Health partnered upwith the Burrell College of Osteopathic Medicine tooffer free flu shots for the publicon Oct. 31.

The event will behappeningata drive-thruclinic locatedat3501 Arrowhead Drive. Flu shots will be availablefor everyone from six months and abovefrom 8:00 a.m. to 12:00 p.m. All attendees are required to wear a mask.

According to David Daniels, disease prevention program manager from the New Mexico Department of Health, there is usually one event like this one per year which is organized by them. Daniels said that this kind of event has been going on for at least 10 years.

Due to COVID-19 and the importance of public health, this year they organized three separate drive-thru clinics. The first one was onOct. 17, another oneOct.24and the upcomingand last oneonOct.31. Thedrive through clinicsareusuallyheld onclosest Saturday to Halloween.

Were only going to do Boo to the Flu events for these dates that we had scheduled, but moving forward, we will have flu vaccines available at our public health office, so this is the one mass vaccination event for the year, Daniels said.

The New Mexico Department of Health recommends that everyone gets their flu shot during these timesspecially since COVID-19 is going around.Free vaccinesare availablethanks to government funds.

We realized that ss long as we can demonstrate what we are doing in the event of an emergency, we could get the community vaccinated for free, and thats what Boo to the Flu turned into, Daniels said.

In the event of a COVID-19 vaccine, the New Mexico Department of Health is more than ready to handle the distributionof said vaccineto theNew Mexico community.

Were looking to have our hospital partners that know how to do these events help us do some of this, Daniels said. At the health departmentwe do this already, with COVID testing, we have a similar process down so we could potentially vaccinate for COVID.

Daniels mentioned that the events have been of great success this year. The programeven ran out of shots to give during one ofthe clinics.Theevent held Oct. 17gathered 1,064 people while the one onOct. 24had 1,800attendeesintotal. Danielsencourages everyone who hasnt gotten their flu shot to attend this Saturday.

In the spirit of Halloween,health care providers at the event will be dressed up in costumes. Everyone who attends is encouraged to wear a costume of their own, especially all children attending.

The rest is here:

Burrell College of Medicine and NMDOH to host free Halloween flu shot clinic - The Round Up

Outlook on the Regenerative Medicine Global Market to 2025 – Impact of COVID-19 on the Market – GlobeNewswire

Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market grew at a CAGR of around 16% during 2014-2019. Regenerative medicine refers to a branch of biomedical sciences aimed at restoring the structure and function of damaged tissues and organs. It involves the utilization of stem cells that are developed in laboratories and further implanted safely into the body for the regeneration of damaged bones, cartilage, blood vessels and organs. Cellular and acellular regenerative medicines are commonly used in various clinical therapeutic procedures, including cell, immunomodulation and tissue engineering therapies. They hold potential for the effective treatment of various chronic diseases, such as Alzheimer's, Parkinson's and cardiovascular disorders (CVDs), osteoporosis and spinal cord injuries.

The increasing prevalence of chronic medical ailments and genetic disorders across the globe is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is prone to various musculoskeletal, phonological, dermatological and cardiological disorders, is stimulating the market growth. In line with this, widespread adoption of organ transplantation is also contributing to the market growth. Regenerative medicine minimizes the risk of organ rejection by the body post-transplant and enhances the recovery speed of the patient.

Additionally, various technological advancements in cell-based therapies, such as the development of 3D bioprinting techniques and the adoption of artificial intelligence (AI) in the production of regenerative medicines, are acting as other growth-inducing factors. These advancements also aid in conducting efficient dermatological grafting procedures to treat chronic burns, bone defects and wounds on the skin. Other factors, including extensive research and development (R&D) activities in the field of medical sciences, along with improving healthcare infrastructure, are anticipated to drive the market further. Looking forward, the publisher expects the global regenerative medicine market to continue its strong growth during the next five years.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global regenerative medicine market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, type, application and end user.

Breakup by Type:

Breakup by Application:

Breakup by End User:

Breakup by Region:

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Allergan PLC (AbbVie Inc.), Amgen Inc., Baxter International Inc., BD (Becton, Dickinson and Company), Integra Lifesciences Holdings Corporation, Medtronic plc, Mimedx Group Inc., Novartis AG, Osiris Therapeutics Inc. (Smith & Nephew plc) and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology 2.1 Objectives of the Study2.2 Stakeholders2.3 Data Sources2.3.1 Primary Sources2.3.2 Secondary Sources2.4 Market Estimation2.4.1 Bottom-Up Approach2.4.2 Top-Down Approach2.5 Forecasting Methodology

3 Executive Summary

4 Introduction4.1 Overview4.2 Key Industry Trends

5 Global Regenerative Medicine Market5.1 Market Overview5.2 Market Performance5.3 Impact of COVID-195.4 Market Forecast

6 Market Breakup by Type6.1 Stem Cell Therapy6.1.1 Market Trends6.1.2 Market Forecast6.2 Biomaterial6.2.1 Market Trends6.2.2 Market Forecast6.3 Tissue Engineering6.3.1 Market Trends6.3.2 Market Forecast6.4 Others6.4.1 Market Trends6.4.2 Market Forecast

7 Market Breakup by Application7.1 Bone Graft Substitutes7.1.1 Market Trends7.1.2 Market Forecast7.2 Osteoarticular Diseases7.2.1 Market Trends7.2.2 Market Forecast7.3 Dermatology7.3.1 Market Trends7.3.2 Market Forecast7.4 Cardiovascular7.4.1 Market Trends7.4.2 Market Forecast7.5 Central Nervous System7.5.1 Market Trends7.5.2 Market Forecast7.6 Others7.6.1 Market Trends7.6.2 Market Forecast

8 Market Breakup by End User8.1 Hospitals8.1.1 Market Trends8.1.2 Market Forecast8.2 Specialty Clinics8.2.1 Market Trends8.2.2 Market Forecast8.3 Others8.3.1 Market Trends8.3.2 Market Forecast

9 Market Breakup by Region9.1 North America9.1.1 United States9.1.1.1 Market Trends9.1.1.2 Market Forecast9.1.2 Canada9.1.2.1 Market Trends9.1.2.2 Market Forecast9.2 Asia Pacific9.2.1 China9.2.1.1 Market Trends9.2.1.2 Market Forecast9.2.2 Japan9.2.2.1 Market Trends9.2.2.2 Market Forecast9.2.3 India9.2.3.1 Market Trends9.2.3.2 Market Forecast9.2.4 South Korea9.2.4.1 Market Trends9.2.4.2 Market Forecast9.2.5 Australia9.2.5.1 Market Trends9.2.5.2 Market Forecast9.2.6 Indonesia9.2.6.1 Market Trends9.2.6.2 Market Forecast9.2.7 Others9.2.7.1 Market Trends9.2.7.2 Market Forecast9.3 Europe9.3.1 Germany9.3.1.1 Market Trends9.3.1.2 Market Forecast9.3.2 France9.3.2.1 Market Trends9.3.2.2 Market Forecast9.3.3 United Kingdom9.3.3.1 Market Trends9.3.3.2 Market Forecast9.3.4 Italy9.3.4.1 Market Trends9.3.4.2 Market Forecast9.3.5 Spain9.3.5.1 Market Trends9.3.5.2 Market Forecast9.3.6 Russia9.3.6.1 Market Trends9.3.6.2 Market Forecast9.3.7 Others9.3.7.1 Market Trends9.3.7.2 Market Forecast9.4 Latin America9.4.1 Brazil9.4.1.1 Market Trends9.4.1.2 Market Forecast9.4.2 Mexico9.4.2.1 Market Trends9.4.2.2 Market Forecast9.4.3 Others9.4.3.1 Market Trends9.4.3.2 Market Forecast9.5 Middle East and Africa9.5.1 Market Trends9.5.2 Market Breakup by Country9.5.3 Market Forecast

10 SWOT Analysis10.1 Overview10.2 Strengths10.3 Weaknesses10.4 Opportunities10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis12.1 Overview12.2 Bargaining Power of Buyers12.3 Bargaining Power of Suppliers12.4 Degree of Competition12.5 Threat of New Entrants12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape14.1 Market Structure14.2 Key Players14.3 Profiles of Key Players14.3.1 Allergan PLC (AbbVie Inc.)14.3.1.1 Company Overview14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis14.3.2 Amgen Inc.14.3.2.1 Company Overview14.3.2.2 Product Portfolio14.3.2.3 Financials 14.3.2.4 SWOT Analysis14.3.3 Baxter International Inc.14.3.3.1 Company Overview14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis14.3.4 BD (Becton, Dickinson and Company)14.3.4.1 Company Overview14.3.4.2 Product Portfolio 14.3.4.3 Financials 14.3.4.4 SWOT Analysis14.3.5 Integra Lifesciences Holdings Corporation14.3.5.1 Company Overview14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis14.3.6 Medtronic Plc14.3.6.1 Company Overview14.3.6.2 Product Portfolio 14.3.6.3 Financials14.3.6.4 SWOT Analysis14.3.7 Mimedx Group Inc.14.3.7.1 Company Overview14.3.7.2 Product Portfolio14.3.7.3 Financials 14.3.8 Novartis AG14.3.8.1 Company Overview14.3.8.2 Product Portfolio 14.3.8.3 Financials14.3.8.4 SWOT Analysis14.3.9 Osiris Therapeutics Inc. (Smith & Nephew plc)14.3.9.1 Company Overview14.3.9.2 Product Portfolio14.3.10 Thermo Fisher Scientific Inc.14.3.10.1 Company Overview14.3.10.2 Product Portfolio 14.3.10.3 Financials14.3.10.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/ywnlq5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Continued here:

Outlook on the Regenerative Medicine Global Market to 2025 - Impact of COVID-19 on the Market - GlobeNewswire

Beat AML Master Clinical Trial Shows Promise for Precision Medicine in the Treatment of AML – Cancer Network

Patients who participated in the Beat AML Master clinical trial were found to have superior outcomes with precision medicine, compared to patients with acute myeloid leukemia (AML) who opted for standard chemotherapy treatment, according to a study published in Nature Medicine.1

Overall, the study demonstrated that a precision medicine therapy strategy in AML is feasible within 7days of sample receipt and before treatment selection, allowing patients and physicians to rapidly incorporate genomic data into treatment decisions without increasing early death or adversely impacting overall survival (OS).

The study shows that delaying treatment up to seven days is feasible and safe, and that patients who opted for the precision medicine approach experienced a lower early death rate and superior overall survival compared to patients who opted for standard of care, corresponding author John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research of The Ohio State University, said in a press release.2 This patient-centric study shows that we can move away from chemotherapy treatment for patients who wont respond or cant withstand the harsh effects of the same chemotherapies weve been using for 40 years and match them with a treatment better suited for their individual case.

In the ongoing Beat AML trial, researchers prospectively enrolled untreated patients with AML who were60 years or older with the aims of providing cytogenetic and mutational data within 7days of the sample receipt and before treatment selection, followed by treatment assignment to a sub-study based on the dominant clone. In total, 487 patients with suspected AML were enrolled in the study and 395 were deemed eligible for analysis.

The median age of the participants was 72 years (range 60-92 years). Overall, 374 patients (94.7%) had genetic and cytogenetic analysis completed within 7days and were centrally assigned to a Beat AML sub-study, while 224 (56.7%) were enrolled on a Beat AML sub-study. The remaining 171 patients elected to receive either standard of care (n = 103), investigational therapy (n = 28), or palliative care (n = 40). Moreover, 9 patients died before treatment assignment.

Demographic, laboratory, and molecular characteristics were not found to be significantly different between patients on the Beat AML sub-studies and those receiving standard of care (induction with cytarabine+daunorubicin [7+3 or equivalent] or hypomethylation agent).

However, 30-day mortality was less frequent, and OS was significantly longer for patients enrolled on the Beat AML sub-studies versus those who elected to receive standard of care. The median OS for patients included in the Beat AML trial was 12.8 months versus 3.9 months for patients opting for standard of care.

To date, the trial has now screened more than 1000 patients at 16 cancer centers. The data presented herein represents patient enrollment during a slice of time between November 17, 2016 and January 30, 2018.

The study is changing significantly the way we look at treating patients with AML, showing that precision medicine, giving the right treatment to the right patient at the right time, can improve short and long-term outcomes for patients with this deadly blood cancer, Louis J. DeGennaro, PhD, president and CEO of the Leukemia & Lymphoma Society (LLS), the conductor of the trial, said in the release. Further, Beat AML has proven to be a viable model for other cancer clinical trials to emulate.

Recently, LLS launched itsBeat COVIDtrial, which leveraged the Beat AML infrastructure to quickly pivot to treat patients with blood cancer who are infected with the coronavirus disease 2019 (COVID-19) virus. The trial is testing the drug acalabrutinib (Calquence), which is currently approved to treat several types of blood cancers. The trial is open to patients diagnosed with all types of blood cancers.

Additionally, LLS is also planning other precision medicine trials modeled after Beat AML, including LLS PedAL, a global precision medicine trial for children with relapsed acute leukemia, currently on track to launch in summer 2021, and Stop MDS, a master trial for patients withmyelodysplastic syndromes.

References:

1. STUDY IN NATURE MEDICINE SHOWS SUPERIOR OUTCOMES FOR PATIENTS IN LLS'S PARADIGM-SHIFTING BEAT AML CLINICAL TRIAL [news release]. Rye Brook, NY. Published October 26, 2020. Accessed October 28, 2020. https://www.lls.org/news/study-in-nature-medicine-shows-superior-outcomes-for-patients-in-llss-paradigm-shifting-beat-aml-clinical-trial?src1=182886&src2=

2. Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nature Medicine. doi: 10.1038/s41591-020-1089-8

See the original post:

Beat AML Master Clinical Trial Shows Promise for Precision Medicine in the Treatment of AML - Cancer Network

Beware the Trojan Horse of Integrative Medicine | Office for Science and Society – McGill Newsroom

The story of the Trojan horse is well known: the Greeks allegedly delivered to the city of Troy a massive wooden horse, which the Trojans mistook for a gift and pulled inside their city. At night, this hollow horse released a band of Greek men who had been hiding inside of it, and they opened the city gates so that their army could strike the final blow in the Trojan War.

The concept of integrative medicine has gained in popularity since it was coined by Dr. Andrew Weil in 1994 and it is important to recognize it as the Trojan horse that it is. Although the metaphor usually implies deception, many fans of integrative medicine promote this gift horse without misleading intentions, but the damage may well be the same.

The claim at the heart of integrative medicine is that conventional medicine is not enough and that so-called complementary and alternative medicine (CAM) is also insufficient, but that by integrating the two, patients get the best of both worlds. Medicine is accused of being hyper-focused on disease and on the use of pharmaceuticals, failing patients with chronic illnesses. CAM is positioned as the answer to this, the yang to conventional medicines yin to yield a complete, holistic perspective.

On its surface, the CAM half of integrative medicine looks wonderful. We are usually told it involves nutrition and exercise. Similarly, proponents of integrative medicine claim its added value is in holism, meaning focusing on the whole person. Strangely though, as has been argued by many people, conventional medicine at its best is focused on the whole person. But integrative medicines seductive, superficial messaging does not end there.

This Trojan horse has been making major in-roads inside of academic hospitals, and it moves on four wheels: the appeals to nature, antiquity, authority, and popularity. Hospital directors and patients alike are told that integrative medicine prioritizes natural treatments... without mentioning that synthesized products are not necessarily harmful and natural ones, not necessarily harmless (or useful). They are told that many of these interventions, like acupuncture, have been used for a long time... just like bloodletting was in ye olden days. They are told that many serious university hospitals, like Johns Hopkins, Duke, and Yale, are already offering integrative medicine... but keeping up with the Joneses is no substitute for a critical appraisal of the body of evidence. And they are told that many, many people are clamouring for these therapies. Market forces being what they are, the Trojan horse rolls into town and we may wonder what pours out of it.

Inside the Trojan horse of integrative medicine, painted in the colours of nutrition and exercise, we find unproven and disproven remedies like homeopathy, the 200-year-old philosophy that claims that the more a substance is diluted, the stronger it becomes. We find Reiki and other energy healing interventions, which pretend that hands-off massages of an undiscovered force field around the body can provide healing. We find poorly regulated herbal remedies, problematic therapies like acupuncture, and things like reflexology, where a foot massage can somehow help your stomach heal itself. The horse also contains more benign interventions, like art therapy and massages, but the majority of CAMs contribution puzzles the mind. These often pre-scientific folkloric therapies often lack plausible mechanisms. Given our extensive knowledge of biology, it makes no sense for the entire human body to be represented on the sole of our feet (see reflexology). Given our extensive knowledge of chemistry, it makes no sense for vast dilutions that leave behind no trace of the ingredient to work (see homeopathy). Yet proponents often throw their hands up when confronted with this and simply claim that it works, how ever it may work.

Universities can easily fall under the spell of integrative medicine because of what I would call the two towers. Imagine two towers that visually represent the evidence we have for conventional medicine and for complementary and alternative medicine, things like homeopathy and Reiki. The conventional medicine tower has an old foundation and is continually being extended and repaired with better materials. By comparison, the CAM towers foundation is made of cheap, imitation material, and while theres a shell that gives it its full height, the bricks have not been laid yet. But the structure is draped in a banner that illustrates what the tower will look like when finished. From a distance, both towers appear similar. Same height, same look. But when you get closer to the CAM tower, you notice how grossly incomplete it is. Dont worry, you are told, what we have so far is very promising and we will keep building it. This slogan never goes away. The CAM tower will always be sold as promising, year after year, convincing many people to invest in it.

Studies of ear acupuncture, craniosacral therapy, homeopathy and many other complementary interventions are usually small, poorly done, and encouraging. When rigorous trials are completed, they fail to demonstrate efficacy, which leads CAM proponents to return to smaller studies and extract hopeful results from those. This tower of promising results can then be presented to academic health centres by philanthropists who believe acupuncture or homeopathy cured them, and their generous donations can lead to the creation of integrative medical centres within these hospitals. Impressive consortia are created to advocate for integrative medicine and to put pressure on medical school curricula to pull the Trojan horse in.

There are clear harms to this. Obviously, if I were to argue that because astronomy is insufficient, it needs to hold hands with astrology in university faculties, it would be easier to see the potential for intellectual harm. Similarly, I have seen Canadians elevating Indigenous ancestral knowledge to the same level as science and asking for its integration into medicine, without testing these claims with the most rigorous tools we have, and I find this equally troublesome

Theres also the financial harm to selling invalid therapies to patients, but perhaps an even bigger eye-opener on the subject of harm is vaccination. Integrative medicine frequently does not embrace immunization, one of the most important public health interventions we have. Dr. Daniel Neides, former director of the Cleveland Clinic Wellness Institute, infamously wrote a furious anti-vaccination screed in 2017 on the website Cleveland.com. Meanwhile, a survey completed by 290 members of the American Board of Integrative and Holistic Medicine revealed them to be more likely than their conventional counterparts to believe misinformation about vaccines (e.g. alternative schedules, toxicities, link to autism). Chiropractors, whose practice is often rolled into integrative medicine, are notorious for harbouring a significant percentage of antivaxxers; ditto for naturopaths. Given how many CAM disciples worship at the altar of Mother Nature and see toxins everywhere, a vote for integrative medicine often risks bolstering unnecessary vaccine hesitancy.

If you are caught looking this Trojan horse in the mouth, the most likely retort you will hear is that conventional medicine has problems. Yes, it does. It is true that medicine does not offer great solutions to many chronic conditions, chief among them chronic pain. Some of its solutions, like opioids, have also caused significant harm because of misplaced economic interests. But the medicine tower gets fixed. Moldy parts are extruded and replaced. Meanwhile, the CAM tower remains deeply flawed and mostly illusory. The bricks are coming, we are told, and soon we will have the proof we need.

If I may bring one more metaphor to this crowded landscape, it would be Dr. Ben Goldacres pearl of wisdom. Problems in aircraft design, he says, do not mean that magic carpets can actually fly. As the Trojan horse of integrative medicine knocks on the doors of our institutions, we must remember that what we need is not a hollow prize with a corrupting cargo; we need to keep fixing the real tower.

Take-home message:-Integrative medicine is a philosophy that advocates for the integration of conventional medical care with numerous complementary and alternative therapies, like Reiki and homeopathy- The evidence for these complementary therapies is often lacking but they keep being sold as a promising solution to the problems of real medicine- Its important to remember that just because there are problems with airplanes, the solution is not to switch to flying carpets

@CrackedScience

Read the rest here:

Beware the Trojan Horse of Integrative Medicine | Office for Science and Society - McGill Newsroom

Runnin’ with Rani: Applying sports medicine in the workplace – West Hawaii Today

Its no surprise that neck, shoulder, and back pain are common complaints among athletes who are constantly training and racing as they push their bodies to the limit. Just ask anyone who has taken a six-hour bike ride to Hawi about the stiffness and soreness they feel afterwards. How about a distance swimmer or a runner training for a marathon?

Yes, we all know the feeling. While having a proper bike fit, stretching and daily foam rolling can help to alleviate common nagging symptoms, most still end up seeing a professional like a chiropractor, massage and physical therapist for relief.

Now, with more people having increased screen time to work, learn and communicate remotely due to COVID-19, these very same symptoms neck, shoulder and back pain have caused an uptick in the number of patients walking through the door of Dr. James Stanleys quaint chiropractic office. And I am one of them.

I have been seeing Dr. Stanley for more than a decade to treat various imbalances associated with running and riding my bike. However, over the last three weeks my visits have been linked to symptoms primarily caused by a drastic increase in sitting while viewing a laptop screen.

I caught up to the busy doctor who kindly shared some sound advice on how to improve ones virtual setup at home or in the office, the importance of allowing your eyes frequent breaks from the screen, and the benefits of exercise to improve mood and motivation.

Q: With more people having to work, learn, and communicate virtually on a daily basis due to COVID-19, what physical ailments do you find are common among teleworkers?

I find that with the COVID -19 pandemic I am seeing a much greater incidence of posture and stress related musculoskeletal complaints in my practice. Common ailments such as headaches, carpal tunnel, piriformis syndrome, sciatica, chronic hip flexor shortening are definitely increased. Upper neck, upper back and lower back are common areas of increased muscle tension and subsequently joint dysfunction with prolonged sitting activity.

When you combine this activity with a poor ergonomic work environment such as a dining table or worse, the results are not great. I have witnessed increased complaints of eye strain with the demands of our teachers setting up learning systems. Some of the complaint is due to simply excessive screen time but some is due to ergonomics of the work environment. Often the workers are setting up multiple screens that are not at an ideal height or positioned too far to one side of their bodies.

Having proper external monitors is critical to surviving the prolonged online activity. Eliminating the need to stare at a laptop monitor is a great first step to improving endurance in this work environment. Adding peripherals such as an external keyboard and mouse are very helpful to achieving a proper posture.

Q: How do these physical ailments negatively affect athlete performance?

Athletic performance is negatively impacted by the effects of chronically tight and imbalanced musculature. Shortened hip flexors, inactivated glutes are just some of the imbalances that can lead to poor form and increase injury in running and other sports. Tightness in the calves can lead to Achilles and plantar fascial issues.

Q: What causes digital eye fatigue and how can one remedy this?

Reading from a screen places unusual demands on the visual system. Minor visual conditions that are not well managed can be more evident. Differences in contrast, brightness and viewing angle from reading a physical print are some of the factors at play.

Improving seating posture and viewing angle can help. Placing the top of the screen at eye level. Make sure your feet are flat on the ground, your back is supported by the chair and your chest is high. When you are in a proper posture your shoulders should not roll forward and your head should feel as if it is floating on your upper body. This head, shoulder and chest posture is also an important part of good running form. Have you heard the phrase Run tall in your shoes?

Q: What can people do to reduce the physical strain from sitting for long periods of time?

Break it up! Try not to spend more than 30 minutes in one position. Get up and walk around the room or stretch lightly then return to the activity. Focus on stretches for hip flexors, air squats to activate your gluteal, shoulder rolls forwards and backwards to mobilize your shoulder and upper thoracic spine. Periodically look outside or even across the room to change your focus distance.

For your wrists and hands, shake them out. Stretch each hand in flexion and extension with the other hand. Place your main monitor as close to center as possible. Bring your mouse and keyboard closer to your body.

Q: Due to current social distancing guidelines and many sporting events canceled, people find themselves more sedentary than ever. What advice can you give?

Lucky we live Hawaii! Get outside. Body weight exercises are a fantastic way to substitute for gym time. I think walking is one of the most underrated exercises. Set a time goal of 20-30 minutes per day and go for a walk. The motivation you will gain from just that activity will improve mood and motivation to do more. It is also a time to set your goals for the post pandemic future. Make yourself some short term actionable physical training goals and some long-term vision goals such as that race you want to do someday.

About Dr. James Stanley

Originally from Washington state, Dr. Stanley holds a doctor of chiropractic degree (DC) and graduated with honors from Palmer College of Chiropractic in Iowa. He has been in practice for 31 years, nineteen of which have been in Hawaii.

Dr. Stanleys practice centers around a functional approach to rehab and performance with emphasis on mobility, ergonomics, balance and strength. He also has additional certification in extremity joint manipulation and management.

Dr. Stanley runs for fitness and other personal interests include songwriting and performing with an original rock band The 1201. His chiropractic practice is located in Pines Plaza of lower Nani Kailua Drive (75-240 Nani Kailua Drive, Suite 3). For more information call 326-9229.

See more here:

Runnin' with Rani: Applying sports medicine in the workplace - West Hawaii Today

Next-gen Precision Medicine Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2018 2028 – Aerospace Journal

Global Next-gen Precision Medicine Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Next-gen Precision Medicine industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/25714

For competitor segment, the report includes global key players of Next-gen Precision Medicine as well as some small players.

Key participants operating in the Next-gen precision medicine market are: F. Hoffmann-La Roche AG, Illumina, Inc, Thermo Fisher Scientific Inc, QIAGEN, Quest Diagnostics, Laboratory Corporation of America Holdings, Novartis AG, AstraZeneca, Bristol-Myers Squibb, Eli Lilly And Company and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Sample Report @ https://www.persistencemarketresearch.co/samples/25714

Important Key questions answered in Next-gen Precision Medicine market report:

What will the market growth rate, Overview, and Analysis by Type of Next-gen Precision Medicine in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Next-gen Precision Medicine market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of Next-gen Precision Medicine market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/25714

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Next-gen Precision Medicine product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Next-gen Precision Medicine , with price, sales, revenue and global market share of Next-gen Precision Medicine in 2019 and 2015.

Chapter 3, the Next-gen Precision Medicine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Next-gen Precision Medicine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, Next-gen Precision Medicine market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe Next-gen Precision Medicine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Continued here:

Next-gen Precision Medicine Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2018 2028 - Aerospace Journal

Nagorno-Karabakh: UK to provide food and medicine to people affected by the conflict – GOV.UK

Thousands of people affected by the Nagorno-Karabakh conflict will receive urgent medical supplies, food and safer shelters from a new UK aid package, announced today by the Foreign Secretary Dominic Raab.

The conflict escalated on 27 September. Since then, tens of thousands of people have been forced to flee their homes, with growing numbers of civilian casualties and damage to homes and vital infrastructure.

Now much-needed medical supplies, including dressing kits and bandages, will be provided for civilians caught up in the crisis through a new 1 million UK aid package, in response to an appeal by the International Committee of the Red Cross (ICRC). People injured in the fighting, including children caught in the crossfire, will receive life-saving treatment at health facilities or from emergency responders supported by the ICRC.

Many of those affected have limited access to food and other essentials, and UK support will provide blankets, food parcels and basic hygiene items to vulnerable communities near to the fighting.

Foreign Secretary Dominic Raab said:

Todays UK aid package will help deliver vital food, medicine and urgent healthcare to those affected by the Nagorno-Karabakh conflict. We continue to urge both sides to engage with the OSCE Minsk group and seek a peaceful, negotiated, political solution which the people of the region so desperately need.

ICRC Regional Director for EURASIA, Martin Schuepp said:

The ICRC is most grateful to the UK for its contribution to the ICRCs response in the region. The high-quality funding the ICRC receives from its donors, including the UK, enables the ICRC to deliver neutral, impartial and independent action to those affected by armed conflict and other situations of violence.

UK support will also help to improve the quality of often overcrowded shelters by installing or improving water tanks and toilets. It will also ensure the shelters are suitably equipped to keep warm as the regions bitter winter approaches.

The UK, along with Canada, has repeatedly called for both sides to work towards a peaceful, political resolution to the conflict through the Organization for Security and Co-operation in Europes (OSCE) Minsk process and has expressed its full support for the work of the Minsk Group.

The new funding is in addition to our core funding to ICRC. In recent years, the UK has been the second largest donor globally to the ICRC, helping them to respond quickly to situations of armed conflict.

The ICRC is an independent, neutral organisation ensuring humanitarian protection and assistance for victims of armed conflict and other situations of violence.

See more here:

Nagorno-Karabakh: UK to provide food and medicine to people affected by the conflict - GOV.UK